Angeles Estelles

USPTO Granted Patents = 10 (Patent Applications = 6)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 1 (Patent Applications = 7)

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 37(Granted Patents)

Company Filing History:

9 out of 28

Trellis Bioscience, Inc.

patents

2 out of 16

Contrafect Corporation

where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12441803 - Engineered CD25 polypeptides and uses thereof (2025-10-14),

2. 12152068 - Binding moieties for biofilm remediation (2024-11-26),

3. 11725055 - Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling (2023-08-15),

4. 11248040 - Binding moieties for biofilm remediation (2022-02-15),

5. 11246928 - Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof (2022-02-15),

6. 11046764 - Native human antibodies for immune checkpoint modulation targets TIM-3 and B7-H3 (2021-06-29),

7. 10858431 - Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling (2020-12-08),

8. 10639370 - Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof (2020-05-05),

9. 10570193 - Binding moieties for biofilm remediation (2020-02-25),

10. 10233234 - Binding moieties for biofilm remediation (2019-03-19),

Title: Angeles Estelles: Pioneering Innovator in the Field of Monoclonal Antibodies

Introduction:

Angeles Estelles, a visionary inventor based in Belmont, CA, is leaving an indelible mark on the realm of medical advancements with his innovative spirit and unwavering commitment to excellence. With a stellar track record of 8 patents to his name, Angeles Estelles is a trailblazer in the field of monoclonal antibodies.

Latest Patents:

His latest patents showcase his groundbreaking work in the medical field, particularly in the development of monoclonal antibodies targeting Killer Immunoglobulin-like Receptor (KIR) family signaling. These antibodies, derived from the native human repertoire, have shown promising results in treating cancer in both humans and other subjects. Additionally, his work on antibodies for influenza virus treatment and prophylaxis further illustrates his dedication to advancing healthcare solutions.

Career Highlights:

Angeles Estelles has made significant contributions to companies such as Trellis Bioscience, Inc. and ContraFect Corporation, where his innovative research and cutting-edge developments have garnered widespread recognition. His expertise in monoclonal antibodies has positioned him as a leading figure in the industry, with a reputation for pushing the boundaries of what is possible in medical science.

Collaborations:

Throughout his illustrious career, Angeles Estelles has collaborated with esteemed colleagues such as Lawrence M. Kauvar and Stefan Ryser. Together, they have shared insights, fostered creativity, and worked tirelessly to bring groundbreaking ideas to fruition. These collaborations have not only enhanced Angeles Estelles' own work but have also inspired the next generation of inventors to think boldly and aspire to greatness.

Conclusion:

Angeles Estelles' passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors in the field of medical research. His pioneering work in monoclonal antibodies stands as a testament to his visionary leadership and unwavering dedication to advancing scientific knowledge for the betterment of humanity. As Angeles Estelles paves the way for future breakthroughs, his legacy serves as a beacon of hope for a brighter, healthier tomorrow.

This text is generated by artificial intelligence and may not be accurate.